TEJAS Journal of Technologies and Humanitarian Science

Artificial Intelligence and Machine Learning for Healthcare Systems: A Study of COVID-19

Abdus Samad Ansari
Zakir Hussain College of Engineering College and Technology (ZHCET), Aligarh Muslim University, Aligarh, India

Author

Mohammad Faiz Umar
Zakir Hussain College of Engineering College and Technology (ZHCET), Aligarh Muslim University, Aligarh, India

Author

📜 License:

This work is licensed under a Creative Commons Attribution 4.0 International License

• Share — Copy and Redistribute the material
• Adapt — Remix, Transform, and build upon the material
• The licensor cannot revoke these freedoms as long as you follow the license terms.

Abstract:

The COVID-19 global pandemic is a threat not only to the health of millions of individuals, but also to the stability of infrastructure and economies around the world. The disease will inevitably place an overwhelming burden on healthcare systems that cannot be effectively dealt with by existing facilities or responses based on conventional approaches. We believe that a rigorous clinical and societal response can only be mounted by using intelligence derived from a variety of data sources to better utilize scarce healthcare resources, provide personalized patient management plans, inform policy, and expedite clinical trials. In this work, we introduce five of the most important challenges in responding to COVID-19 and show how each of them can be addressed by recent developments in machine learning (ML) and artificial intelligence (AI). We argue that the integration of these techniques into local, national, and international healthcare systems will save lives, and propose specific methods by which implementation can happen swiftly and efficiently. We offer to extend these resources and knowledge to assist policymakers seeking to implement these techniques.

References

[1] F. Jiang, L. D., L. Z., Y. C., W. C. Chi, and Z. X., “Review of the clinical characteristics of coronavirus disease (COVID-19),” Journal of General Internal Medicine, 2020, pp. 1–5.

[2] M. Wang, Q. Z., W. C., J. P., H. W., C. S., and D. R., “Building the Knowledge Graph for UK Health Data Science,” ERA, 2020.

[3] M. A. Ahmed and M. van der Schaar, “Bayesian inference of individualized treatment effects using multi-task Gaussian processes,” in NeurIPS, 2017.

[4] M. A. Ahmed and M. van der Schaar, “Discriminative Jackknife: Quantifying uncertainty in deep learning via higher order influence functions,” 2020.

[5] A. M. Alaa and M. van der Schaar, “AutoPrognosis: Automated clinical prognostic modeling via Bayesian optimization with structured kernel learning,” 2018.

[6] A. M. Alaa and M. van der Schaar, “Attentive state-space modeling of disease progression,” in Advances in Neural Information Processing Systems, 2019.

[7] A. M. Alaa and M. van der Schaar, “Frequentist uncertainty in recurrent neural networks via blockwise influence functions,” 2020.

[8] A. M. Alaa, J. Yoon, S. Hu, and M. van der Schaar, “Personalized risk scoring for critical care prognosis using mixtures of Gaussian processes,” IEEE Transactions on Biomedical Engineering, 2017.

[9] A. M. Alaa, K. Ahuja, and M. van der Schaar, “A micro-foundation of social capital in evolving social networks,” IEEE Transactions on Network Science and Engineering, vol. 5, no. 1, pp. 14–31, 2018.

[10] R. M. Anderson, H. H., D. K., and T. D. Hollingsworth, “How will country-based mitigation measures influence the course of COVID-19,” 2020.

[11] O. Atan, W. R. Zame, and M. van der Schaar, “Sequential patient recruitment and allocation for adaptive clinical trials,” in AISTATS, 2019.

[12] A. Bellot and M. van der Schaar, “Flexible modelling of longitudinal medical data: A Bayesian nonparametric approach,” ACM Transactions on Computing for Healthcare, 2020.

[13] I. Bica, A. M. Alaa, J. Jordon, and M. van der Schaar, “Estimating counterfactual treatment outcomes over time through adversarially balanced representations,” 2020.

[14] I. Bica, D. Jarrett, A. Hüyük, and M. van der Schaar, “Batch inverse reinforcement learning using counterfactuals for understanding decision making,” 2020.

[15] A. Chan, A. M. Alaa, and M. van der Schaar, “Unlabelled data improves Bayesian uncertainty calibration under covariate shift,” 2020.

[16] N. M. Ferguson et al., “Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand,” Imperial College COVID-19 Response Team, London, Mar. 16, 2020.

[17] J. Gao, Z. T., and Y. Xu, “Chloroquine phosphate efficacy in COVID-19 treatment,” BioScience Trends, 2020.

[18] L. B. Goldstein, G. P. Samsa, D. B. Matchar, and R. D. Horner, “Charlson Index comorbidity adjustment for ischemic stroke outcome studies,” Stroke, vol. 35, no. 8, pp. 1941–1945, 2004.

[19] A. Hüyük, D. Jarrett, and M. van der Schaar, “Explaining by imitating: Understanding decisions by direct policy learning,” Preprint, 2020.

[20] D. Jarrett and M. van der Schaar, “Inverse active sensing: Modeling and understanding timely decision-making,” Preprint, 2020.

[21] Z. Qian et al., “Learning dynamic and personalized comorbidity networks using deep diffusion processes,” in AISTATS, 2020.

[22] Z. Qian, A. M. Alaa, M. van der Schaar, and A. Ercole, “Between-centre differences for COVID-19 ICU mortality,” Intensive Care Medicine, 2020.

[23] M. Wang et al., “Building the Knowledge Graph for UK Health Data Science,” ERA, 2020.